Skylet Pharma Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
- Paid Up Capital ₹ 0.10 M
- Company Age 4 Year, 2 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 4.90 M
- Revenue Growth 816.23%
- Profit Growth 38.43%
- Ebitda 100.06%
- Net Worth 74.27%
- Total Assets 158.97%
About Skylet Pharma
Skylet Pharma Private Limited (SPPL) is a Private Limited Indian Non-Government Company incorporated in India on 23 November 2020 (Four years and two months 10 days old ). Its registered office is in Raigarh, Maharashtra, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹4.90 M.
Lalluprasad Maurya and Shiv Shankar serve as directors at the Company.
Company Details
-
Location
Raigarh, Maharashtra, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U51909MH2020PTC350510
-
Company No.
350510
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
23 Nov 2020
-
Date of AGM
30 Sep 2023
-
Date of Balance Sheet
31 Mar 2023
-
Listing Status
Unlisted
-
ROC Code
Roc Mumbai
Industry
Who are the key members and board of directors at Skylet Pharma?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Lalluprasad Maurya
|
Director | 23-Nov-2020 | Current |
|
Shiv Shankar
|
Additional Director | 13-Sep-2023 | Current |
Financial Performance of Skylet Pharma.
Skylet Pharma Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 816.23% increase. The company also saw a substantial improvement in profitability, with a 38.43% increase in profit. The company's net worth Soared by an impressive increase of 74.27%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Skylet Pharma?
In 2022, Skylet Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
₹4.90 M
₹0
Charges Breakdown by Lending Institutions
- Axis Bank Limited : 0.49 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 01 Jul 2023 | Axis Bank Limited | ₹4.90 M | Open |
How Many Employees Work at Skylet Pharma?
Skylet Pharma has a workforce of 0 employees as of Apr 02, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Skylet Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Skylet Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
